I really missed an opportunity on ACAD back in nov/dec when I told my boss at work about it. I liked it, but some of the trial results were sketchy.. They reworked numbers from a trial for only North America...because the ROW numbers were a flop. Regardless... It is pretty much as high as it can go for a long long while here. I'd actually short it before I went long. The upside in KERX is much higher! I'll just stay here until a double digit buyout.